GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS-3583 in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 13
- Registration Number
- NCT04747470
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸NEXT oncology, San Antonio, Texas, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)
- Conditions
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 249
- Registration Number
- NCT04745351
- Locations
- 🇺🇸
Holy Cross Hospital, Silver Spring, Maryland, United States
🇺🇸MedStar Health Research Institute, Washington, District of Columbia, United States
🇺🇸George Washington Medical Faculty Associates, Washington, District of Columbia, United States
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
- Conditions
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 331
- Registration Number
- NCT04639986
- Locations
- 🇨🇳
Affiliated Tumor Hospital of Xinjiang Medical University, Ürümqi, China
🇰🇷Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
- Conditions
- Interventions
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT04617522
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸Pacific Shores Medical Group, Long Beach, California, United States
🇺🇸Christiana Care Health Services, Newark, Delaware, United States
Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 27
- Registration Number
- NCT04608344
- Locations
- 🇺🇸
Prism Research, LLC, Saint Paul, Minnesota, United States
Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation
- First Posted Date
- 2020-09-04
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 156
- Registration Number
- NCT04539262
- Locations
- 🇺🇸
Aurora FDRC Inc., Costa Mesa, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Research in Miami, Inc., Hialeah, Florida, United States
Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice in Participants With Metastatic or Locally Advanced Unresectable Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 696
- Registration Number
- NCT04527991
- Locations
- 🇺🇸
Mayo Clinic - Arizona, Phoenix, Arizona, United States
🇺🇸University of California Irvine (UCIMC), Orange, California, United States
🇺🇸MedStar Washington Hospital Center, Washington, District of Columbia, United States
Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 9
- Registration Number
- NCT04502706
- Locations
- 🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 584
- Registration Number
- NCT04501952
- Locations
- 🇺🇸
Mills Clinical Research, Los Angeles, California, United States
🇺🇸NorthStar Medical Center, Chicago, Illinois, United States
🇺🇸University of Maryland Baltimore, Baltimore, Maryland, United States
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Gilead Sciences
- Registration Number
- NCT04483687